224 related articles for article (PubMed ID: 22892843)
1. Cancer cell spheroids as a model to evaluate chemotherapy protocols.
Perche F; Torchilin VP
Cancer Biol Ther; 2012 Oct; 13(12):1205-13. PubMed ID: 22892843
[TBL] [Abstract][Full Text] [Related]
2. Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model.
Perche F; Patel NR; Torchilin VP
J Control Release; 2012 Nov; 164(1):95-102. PubMed ID: 22974689
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models.
Sarisozen C; Dhokai S; Tsikudo EG; Luther E; Rachman IM; Torchilin VP
Eur J Pharm Biopharm; 2016 Nov; 108():54-67. PubMed ID: 27569031
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin-mediated radiosensitivity in multicellular spheroids from a lung cancer cell line is enhanced by composite micelle encapsulation.
Xu WH; Han M; Dong Q; Fu ZX; Diao YY; Liu H; Xu J; Jiang HL; Zhang SZ; Zheng S; Gao JQ; Wei QC
Int J Nanomedicine; 2012; 7():2661-71. PubMed ID: 22679376
[TBL] [Abstract][Full Text] [Related]
5. Antitumor drug delivery in multicellular spheroids by electropermeabilization.
Gibot L; Wasungu L; Teissié J; Rols MP
J Control Release; 2013 Apr; 167(2):138-47. PubMed ID: 23385033
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.
Eng C; Mauer AM; Fleming GF; Bertucci D; Rotmensch J; Jacobs RH; Ratain MJ
Ann Oncol; 2001 Dec; 12(12):1743-7. PubMed ID: 11843253
[TBL] [Abstract][Full Text] [Related]
7. Enhanced targeting of 3D pancreatic cancer spheroids by aptamer-conjugated polymeric micelles with deep tumor penetration.
Tian L; Pei R; Zhong L; Ji Y; Zhou D; Zhou S
Eur J Pharmacol; 2021 Mar; 894():173814. PubMed ID: 33352182
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin and α-Mangostin oppositely affect luminal breast cancer cell stemness evaluated by a new retinaldehyde-dependent ALDH assay in MCF-7 tumor spheroids.
Bissoli I; Muscari C
Biomed Pharmacother; 2020 Apr; 124():109927. PubMed ID: 31982725
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil).
Tsukioka Y; Matsumura Y; Hamaguchi T; Koike H; Moriyasu F; Kakizoe T
Jpn J Cancer Res; 2002 Oct; 93(10):1145-53. PubMed ID: 12417045
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of the therapeutic effect of Doxorubicin and Resveratrol combination on 2D and 3D (spheroids) cell culture models.
Barros AS; Costa EC; Nunes AS; de Melo-Diogo D; Correia IJ
Int J Pharm; 2018 Nov; 551(1-2):76-83. PubMed ID: 30217766
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Combination of Doxorubicin and Paclitaxel Delivered by Blood Brain Barrier and Glioma Cells Dual Targeting Liposomes for Chemotherapy of Brain Glioma.
Chen X; Yuan M; Zhang Q; Ting Yang Y; Gao H; He Q
Curr Pharm Biotechnol; 2016; 17(7):636-50. PubMed ID: 27033513
[TBL] [Abstract][Full Text] [Related]
12. Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.
Casagrande N; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Clin Cancer Res; 2014 Nov; 20(21):5496-506. PubMed ID: 25231401
[TBL] [Abstract][Full Text] [Related]
13. Citral induced apoptosis in MDA-MB-231 spheroid cells.
Nigjeh SE; Yeap SK; Nordin N; Kamalideghan B; Ky H; Rosli R
BMC Complement Altern Med; 2018 Feb; 18(1):56. PubMed ID: 29433490
[TBL] [Abstract][Full Text] [Related]
14. A stimuli-responsive combination therapy for recovering p53-inactivation associated drug resistance.
Guo L; Xu Y; Zhou A; Zhang L; Sun L; Gao Y; Chen J; Shan X; Zhang J; Ge J; An X; Liu X; Zhang Y; Ning X
Mater Sci Eng C Mater Biol Appl; 2020 Mar; 108():110403. PubMed ID: 31923941
[TBL] [Abstract][Full Text] [Related]
15. Role of intercellular communications in breast cancer multicellular tumor spheroids after chemotherapy.
Oktem G; Bilir A; Ayla S; Yavasoglu A; Goksel G; Saydam G; Uysal A
Oncol Res; 2006; 16(5):225-33. PubMed ID: 17294803
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
Holmes FA
Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
[TBL] [Abstract][Full Text] [Related]
17. Sonoprinting liposomes on tumor spheroids by microbubbles and ultrasound.
Roovers S; Deprez J; Priwitaningrum D; Lajoinie G; Rivron N; Declercq H; De Wever O; Stride E; Le Gac S; Versluis M; Prakash J; De Smedt SC; Lentacker I
J Control Release; 2019 Dec; 316():79-92. PubMed ID: 31676384
[TBL] [Abstract][Full Text] [Related]
18. Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro.
Akutsu M; Kano Y; Tsunoda S; Suzuki K; Yazawa Y; Miura Y
Eur J Cancer; 1995 Dec; 31A(13-14):2341-6. PubMed ID: 8652267
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal Antibody 2C5-Modified Mixed Dendrimer Micelles for Tumor-Targeted Codelivery of Chemotherapeutics and siRNA.
Pan J; Attia SA; Subhan MA; Filipczak N; Mendes LP; Li X; Kishan Yalamarty SS; Torchilin VP
Mol Pharm; 2020 May; 17(5):1638-1647. PubMed ID: 32233497
[TBL] [Abstract][Full Text] [Related]
20. Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide.
Hussein MA
Oncologist; 2003; 8 Suppl 3():39-45. PubMed ID: 14671227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
